Investigational drug · Phase 2
YK012
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Systemic Lupus Erythematosus (SLE), B-cell Acute Lymphoblastic Leukemia.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "YK012"
First trial start
2024
Sep 25, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "YK012", any sponsor or status.
Conditions studied
As listed on its trial records.
- Systemic Lupus Erythematosus (SLE)
- B-cell Acute Lymphoblastic Leukemia
Approved drugs for the same conditions: Acute lymphoblastic leukemia · Lupus (SLE) · Hematology and blood cancers · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "YK012" as an intervention, largest first.
Excyte Biopharma LtdIndustry
NCT07010835 · 189 participants (planned) · Start Aug 25, 2025 · Primary completion Jun 2027
Drug: YK012 · For: Systemic Lupus Erythematosus (SLE)
Sites: Beijing, China
Excyte Biopharma LtdIndustry
NCT06982729 · 72 participants (planned) · Start Mar 8, 2025 · Primary completion Dec 2026
Drug: YK012 · For: Primary Membranous Nephropathy
Sites: Beijing, China
- A Phase I Study of YK012 in Primary Membranous NephropathyNot yet recruiting
Excyte Biopharma LtdIndustry
NCT07234474 · 66 participants (planned) · Start Sep 2027 · Primary completion Oct 2028
Drug: YK012 · For: Primary Membranous Nephropathy
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012Recruiting
Excyte Biopharma LtdIndustry
NCT06565689 · 48 participants (planned) · Start May 9, 2023 · Primary completion Dec 2028
Drug: YK012 · For: Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Sites: Beijing, China
Excyte Biopharma LtdIndustry
NCT06580301 · 46 participants (planned) · Start Sep 25, 2024 · Primary completion Dec 31, 2026
Drug: YK012 · For: B-cell Acute Lymphoblastic Leukemia
Sites: Guangzhou, China; Guiyang, China; Zhengzhou, China · 12 sites in all
- Study of YKST02 Alone or in Combination With YK012 in Patients With Active or Refractory Systemic Lupus ErythematosusNot yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT07512947 · 30 participants (planned) · Start May 2026 · Primary completion Mar 30, 2028
Drug: YKST02; YK012 · For: System Lupus Erythematosus(SLE)
Sites: Wuhan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Systemic Lupus Erythematosus (SLE)
- hUC-MSCsmesenchymal stem cells, MSCPhase 38 trials
Shenzhen Wingor Biotechnology Co., Ltd. · Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)
- EnpatoranM5049, M5049 dosePhase 35 trials
EMD Serono Research & Development Institute, Inc. · Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus
- LitifilimabBIIB059Phase 35 trials
Biogen · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus, Lupus Erythematosus, Systemic
- SCTC21CPhase 34 trials
Sinocelltech Ltd. · IgA Nephropathy, Multiple Myeloma (MM), Systemic Lupus Erythematosus (SLE)
- SG301Phase 33 trials
Hangzhou Sumgen Biotech Co., Ltd. · Systemic Lupus Erythematosus (SLE), Relapsed/Refractory Multiple Myeloma, Antibody Mediated Rejection
- Descartes-08Phase 24 trials
Cartesian Therapeutics · Myasthenia Gravis, Generalized, Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV)
- ESG206ESG206-2Phase 23 trials
Shanghai Escugen Biotechnology Co., Ltd · Systemic Lupus Erythematosus (SLE), Immune Thrombocytopenia (ITP), Primary Sjögren Syndrome
- BCMA-CD19-IL-15Phase 22 trials
iCell Gene Therapeutics · Inflammatory Bowel Diseases (IBD), Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.